Company description

Adverum Biotechnologies Inc. (ADVM) is a clinical-stage gene therapy company that focuses on developing innovative treatments for patients with serious eye and rare diseases. The company utilizes its proprietary gene therapy platform to engineer long-lasting and transformative therapies that can potentially halt the progression of diseases or restore functional vision. ADVM's lead candidate, ADVM-022, is currently in Phase 1 and 2 clinical trials for the treatment of wet age-related macular degeneration (wet AMD). The company is also advancing programs in other retinal and rare diseases, including optic neuropathy and alpha-1 antitrypsin deficiency. Along with its strong pipeline, ADVM has established strategic partnerships with renowned companies such as Regeneron Pharmaceuticals to accelerate the development of its therapies. The company's pioneering approach and dedication to addressing unmet medical needs have garnered recognition from the scientific community and investors alike. With a team of experienced leaders and impressive research capabilities, ADVM is poised to lead the way in the development of life-changing gene therapies.